Get the Stockscreener App
110.91
1.08%
1.19
After Hours:
110.75
-0.16
-0.14%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $110.91, with a volume of 6.61M.
It is up +1.08% in the last 24 hours and up +18.08% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$109.72
Open:
$108.05
24h Volume:
6.61M
Relative Volume:
0.54
Market Cap:
$191.92B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
35.85
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
+4.92%
1M Performance:
+18.08%
6M Performance:
-0.50%
1Y Performance:
-15.35%
1-Day Range:
$107.50
$111.28
1-Week Range:
$105.56
$111.28
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
110.91 | 189.86B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
347.21 | 133.54B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.76 | 116.07B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.42 | 74.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
93.05 | 53.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
The Abbott Big Ten $1 Million Blood Drive is Back - Sports Illustrated
Abbott, Google Health Join Forces on AI-Powered Metabolic Health - Medical Product Outsourcing
Abbott, Google to combine glucose data with AI coaching - MedTech Dive
What Abbott Laboratories (ABT)'s AI-Powered Google Health Partnership Means For Shareholders - simplywall.st
Every 2 Seconds, Someone in the U.S. Needs Blood as Abbott Drive Returns - Stock Titan
Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis - PR Newswire
Abbott and Google Health partner for glucose monitoring solutions - Yahoo Tech
Abbott Laboratories $ABT Shares Sold by West Branch Capital LLC - marketbeat.com
Butensky & Cohen Financial Security Inc. Purchases 9,277 Shares of Abbott Laboratories $ABT - marketbeat.com
Abbott Laboratories (NYSE:ABT) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
July Jobs Report Stirs Recession Fears: Why J&J and Abbott May Offer Shelter - finance.biggo.com
Abbott, Mead Must Face Baby Formula Retrial, Mo. Panel Says - Law360
The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession - The Motley Fool
Google Health Partners with Global Healthcare Company Abbott - jetstream.blog
Abbott Laboratories (ABT) schedules NYSE sale of stock from vested awards - Stock Titan
The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession - The Motley Fool
Abbott Partners With Google Health For AI-Powered Glucose Monitoring - Engadget
Abbott to integrate Google’s AI health coach into wearable glucose monitoring tech - Crain's Chicago Business
Abbott and Google join forces to deliver AI-powered glucose insights - Cardiovascular Business
Abbott teams up with Google Health to improve Lingo - marketscreener.com
Why is Abbott Laboratories stock gaining today? - Investing.com
Why is Abbott Laboratories stock gaining today? By Investing.com - Investing.com India
Google Health announces a strategic partnership with Abbott, a leader in health and wellness. - blog.google
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI - Abbott MediaRoom
Abbott and Google Launch First-of-its-Kind Partnership to Transform Everyday Health Through Glucose Insights and AI - marketscreener.com
Abbott Laboratories price shows more positive signalsForecast today11-08-2026 - Economies.com
Handelsbanken Fonder AB Sells 444,592 Shares of Abbott Laboratories $ABT - marketbeat.com
Abbott Laboratories (ABT) Just Gave Investors Something To Think About - simplywall.st
Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story? - Yahoo Finance
Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings? - Yahoo Finance
Abbott Continues to Oppose Spinal Cord Stimulator Lawsuit MDL, Despite Mounting Claims - AboutLawsuits.com
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom? - TradingView
Abbott Laboratories (ABTCL.SN) stock price, news, quote and history - Yahoo Finance UK
Vertrix Wealth Management LLC Invests $2.67 Million in Abbott Laboratories $ABT - marketbeat.com
Abbott Laboratories (ABT) Stock Analysis: Exploring a 9.84% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update - Yahoo Finance
Gradient Investments LLC Sells 126,411 Shares of Abbott Laboratories $ABT - marketbeat.com
Abbott Laboratories $ABT Shares Bought by Rockland Trust Co. - marketbeat.com
3 Inflation Resilient Dividend Stocks Offering Steady Income as CPI and Rate Risks Loom - simplywall.st
NewEdge Advisors LLC Has $27.81 Million Stock Holdings in Abbott Laboratories $ABT - marketbeat.com
Chesley Taft & Associates LLC Raises Holdings in Abbott Laboratories $ABT - marketbeat.com
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? - fool.com
Abbott (ABT) Stock Trades At A Cash Flow Discount But An Earnings Premium - simplywall.st
What Makes Abbott Laboratories (ABT) a Compelling Investment Opportunity with Reliable Growth - Yahoo Finance
Czech National Bank Raises Holdings in Abbott Laboratories $ABT - marketbeat.com
PensionDanmark Pensionsforsikringsaktieselskab Raises Position in Abbott Laboratories $ABT - marketbeat.com
51,393 Shares in Abbott Laboratories $ABT Purchased by St. Louis Financial Planners Asset Management LLC - marketbeat.com
Assenagon Asset Management S.A. Sells 1,210,999 Shares of Abbott Laboratories $ABT - marketbeat.com
Avior Wealth Management LLC Lowers Stake in Abbott Laboratories $ABT - marketbeat.com
US companies face rise in cyber attacks - Reuters
Abbott Laboratories stock outperforms competitors on strong trading day - marketwatch.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):